Cyprotex

Cyprotex

Established in 1999, Cyprotex Limited was acquired by Evotec (www.evotec.com) in 2016. Cyprotex, an Evotec company, has sites at Alderley Park near Macclesfield, UK and in Watertown near Boston, USA. The company has dedicated and highly qualified employees with proven experience in a wide range of specialist techniques acquired across diverse industries. The majority of our clients focus in pharmaceutical research, however, we also support clients in the chemical, cosmetics and personal care, agrichemical and tobacco industries. Cyprotex specialises in in vitro and in silico ADME-Tox services. This includes in vitro ADME and safety screening to support discovery projects, regulatory in vitro ADME and DDI studies during preclinical and clinical development, specialist techniques for assessing mechanisms of in vitro human and animal toxicity (e.g. transcriptomics, 3D models and MEA electrophysiology) and PBPK/QSAR modelling expertise. Further information on Cyprotex is available on our website at www.cyprotex.com.

ADME (Absorption/Distribution/Metabolism/Excretion), Bioanalytical Services, CRO—Contract Research Organization, Cardiology/Cardiotoxicology, In Vitro Metabolism, In Vitro Research/Testing, Modeling Products/Services, Neurobiology/Neurotoxicology, Preclinical Research/Testing, Safety Assessment